In short
Clinical trials are studying ABBV-8736 in adults with moderate to severe Crohn’s disease. These studies aim to check safety, efficacy, and how the treatment affects the disease. The trial data here describe a Phase 2 study in a large adult population.
Key points
- ABBV-8736 is being studied in a Phase 2 clinical trial for adults with moderate to severe Crohn’s disease. The study is authorised and plans to enroll 1,072 participants. Researchers want to learn about safety, efficacy, and the treatment’s mechanistic profile, which means how it may affect the disease process. The main endpoint is endoscopic remission at Week 12. This trial is part of a broader study of targeted therapies for Crohn’s disease.
Trial overview
This is an interventional study, which means researchers give study treatment and then measure the results in participants. The trial is authorised and is studying adults with moderate to severe Crohn’s disease.
The study title says it is looking at targeted therapies for treatment of this condition, and the brief summary says the goal is to evaluate safety, efficacy, and the mechanistic profile of the studied therapies. ABBV-8736 is one of the listed study drugs in this trial.
Who can participate
The source data show that the target population is adult participants with moderate to severe Crohn’s disease. No other eligibility details are provided in the trial information given here.
What the study measures
The main endpoint is endoscopic remission at Week 12. Endoscopic remission means that a scope exam of the bowel shows little or no active disease.
The study also aims to assess safety and efficacy. Safety means watching for problems during the study, while efficacy means how well the treatment works for the disease.
Trial phase and size
This study is in Phase 2. Phase 2 trials usually focus on whether a treatment may work and continue to collect safety information.
The planned enrollment is 1,072 participants. Enrollment means the number of people the study hopes to include.
Study treatments
ABBV-8736 is listed among several targeted therapies in the study. The other listed treatments are ABBV-066, Lutikizumab, ABBV-382, and ABBV-066 with Risankizumab.
The source data list different ways these study drugs are given, including intravenous use, subcutaneous injection, and intramuscular use. These are ways medicine can be given into a vein, under the skin, or into a muscle.
Why this trial matters
People with moderate to severe Crohn’s disease often need treatments that reduce bowel inflammation and improve disease control. This study is designed to help researchers learn whether ABBV-8736 and the other targeted therapies can help with that goal.
Because the study measures endoscopic remission, it looks not only at symptoms but also at what is seen directly inside the bowel. That can give a clearer picture of whether the disease is truly improving.